We were not able to find an announced earnings date for this symbol yet. Check back again later
Company Info
CEO
N/A
Location
Florida, USA
Exchange
OTC
Website
https://earthsciencetech.com
Summary
Earth Science Tech, Inc.
Company Info
CEO
N/A
Location
Florida, USA
Exchange
OTC
Website
https://earthsciencetech.com
Summary
Earth Science Tech, Inc.
AI Insights for ETST
6 min read
Quick Summary
Earth Science Tech, Inc. is an OTC-listed U.S. company that has evolved from a nutraceuticals, bioceuticals, hemp-derived products, and dietary-supplement business into a holding-company model focused on healthcare and related services. The company’s legacy product areas include cannabidiol oils, vitamins, minerals, herbs, botanicals, personal-care products, homeopathic items, functional foods, and wellness supplements sold to retailers and end consumers. Recent company commentary indicates that ETST also owns or operates subsidiaries involved in compounding pharmacy, telehealth, consumer products, investment management, and real estate, including RxCompoundStore, Mister Meds, Peaks Curative, DOConsultation, Avenvi, and MagneChef. Its customers appear to include online patients seeking telehealth prescriptions, consumers buying wellness or supplement products, retail partners in niche health categories, and healthcare-related businesses that use compounded pharmaceutical services. ETST is a very small company by employee count but reports meaningful revenue and profitability relative to its market capitalization, with operating revenue of about $9.0 million and net income of about $0.7 million in the provided data. The business is therefore best understood as a small, diversified OTC healthcare and wellness holding company with exposure to supplements, telemedicine, compounding pharmacy, and real estate-backed expansion.
Strengths
•
ETST’s main strength is its diversified holding-company structure, which gives it exposure to multiple healthcare and consumer markets rather than a single product line.
•
The combination of telehealth demand generation and internal pharmacy fulfillment could improve margins, increase customer retention, and create operational synergies.
•
The provided financial data show positive earnings, positive operating income, a meaningful gross-profit base, and valuation ratios that may appear inexpensive compared with many growth-oriented healthcare peers.
•
Management has also described a strong balance sheet and an ongoing buyback, which can support investor confidence if executed transparently.
•
The company’s small size may allow it to move quickly into niche categories such as customized compounded products, discreet telehealth treatments, and specialized wellness offerings.
Risks
•
ETST’s weaknesses include its OTC listing, limited liquidity, small employee count, and potentially limited access to institutional capital.
•
The company operates across several very different business lines, which can make execution more complex and make it harder for investors to understand the core value driver.
•
Some of its historical product categories, such as CBD, supplements, and wellness claims, are highly competitive and can be vulnerable to regulatory scrutiny or changing consumer preferences.
•
The data also show missing or unavailable fields such as CEO in the fundamental dataset, beta, next earnings date, and dividend information, which may reduce transparency for some investors.
•
The holding-company model can create integration risk if subsidiaries do not share systems, compliance processes, customer data, or financial discipline effectively.
Key Risks
•
ETST faces significant regulatory risk because compounding pharmacies, telehealth prescribing, dietary supplements, CBD-related products, and healthcare marketing are all subject to changing rules and enforcement priorities.
•
Any compliance failure, product-quality issue, prescription-rule violation, or adverse inspection outcome could damage operations and reputation.
•
The company also faces execution risk from integrating multiple subsidiaries across healthcare, consumer products, real estate, and investment activities.
•
Competitive pressure from larger telehealth platforms, better-capitalized compounding pharmacies, and established supplement brands could increase marketing costs and reduce margins.
What to Watch
The most recent provided fundamental period is labeled Year 2027 Q2, and the data show ETST generated about $9.0 million in revenue, about $6.3 million in gross profit, about $0.6 million in operating income, and about $0.7 million in net income.
These figures suggest the company was profitable during the reported period, which is important for a small OTC issuer with only three listed employees in the dataset.
Recent company news emphasized ETST’s transition toward a diversified holding-company structure that includes compounding pharmacy, telehealth, real estate, investment management, and consumer products.
Management discussed vertical integration in which telehealth platforms generate demand for compounded products fulfilled by RxCompoundStore and Mister Meds.
Peaks Curative was reported to have become profitable and cash-flow positive, while DOConsultation and Mister Meds were expected to contribute soon.
Another recent event was the Phase II upgrade of PeakNow.com, which expanded erectile-dysfunction treatments with Tadalafil and Sildenafil options in multiple formats and quantities.
Price Drivers
•
ETST’s stock price is likely driven first by reported profitability, revenue growth, and valuation metrics because the provided data show positive net income, EPS, and a relatively low price-to-earnings ratio.
•
Investors may focus on whether the company can sustain roughly $9.0 million in revenue, maintain strong gross profit, and convert operating income into free cash flow.
•
The company’s OTC listing can make the stock more volatile because liquidity is limited, the investor base may be smaller, and price moves can be amplified by modest trading volume.
•
Recent management commentary about a holding-company model, vertical integration, profitability at Peaks, an ongoing buyback, and a strong balance sheet may also influence sentiment.
•
Broader market trends in telehealth, compounded drugs, consumer wellness, CBD products, and affordable housing can affect how investors value ETST’s diversified business mix.
•
Regulatory developments affecting compounding pharmacies, telemedicine prescribing, dietary supplements, and hemp-derived products could quickly change investor expectations and valuation multiples.
Recent News
•
Recent news highlighted an interview in which CEO Giorgio Saumat described ETST as a holding company with subsidiaries in compounding pharmacy, telehealth, real estate, investment management, and consumer products.
•
He said growth is being driven by vertical integration in healthcare, where telehealth platforms create demand for compounded products fulfilled by RxCompoundStore and Mister Meds.
•
Management stated that Peaks Curative recently became profitable and cash-flow positive, while DOConsultation and Mister Meds are expected to contribute in the future.
•
The company also discussed Avenvi’s real estate activities, including pharmacy-related assets in Texas and affordable residential development projects in Florida.
•
Another recent update said PeakNow.com launched a Phase II upgrade with expanded erectile-dysfunction treatments, including Tadalafil gummies and tablets as well as Sildenafil capsules and tablets.
•
Older product-related news also described OxyBiotic, a dietary supplement positioned as an oxygen-based colon cleanser with probiotics, although its claims are not FDA-evaluated and it is not intended to diagnose, treat, or cure disease.
Market Trends
•
ETST is affected by the growth of telehealth, as consumers increasingly expect digital consultations, fast prescription access, discreet fulfillment, and home delivery.
•
The company is also influenced by the expanding but scrutinized compounding-pharmacy market, where personalized formulations can be attractive but regulatory oversight remains intense.
•
Consumer interest in wellness, probiotics, supplements, functional foods, and alternative health products supports demand for ETST’s legacy categories, though the market is crowded and marketing claims must be carefully managed.
•
Demand for men’s health, erectile-dysfunction treatments, weight-management products, and online prescription services has grown as patients become more comfortable with direct-to-consumer healthcare.
•
Higher interest rates and housing affordability challenges affect ETST’s real estate ambitions, creating both opportunities for affordable housing and risks from financing and construction costs.
•
Broader OTC market conditions, investor appetite for micro-cap healthcare stocks, and trust in management transparency will also shape how the market values ETST.
AI-generated summary for educational purposes only. Not investment advice. Always do your own research before investing.
Community Research
Research from investors like you
Be the first to share your analysis on ETST
Help fellow investors make informed decisions by sharing your research on fundamentals, catalysts, and outlook.
